insert therapeutics unidym tego bio sciences science research anti-cancer drugs RNAi therapeutics carbon-based electronics nanotechnology arrowhead pasadena california nasdaq arwr nanotechnology arrowhead pasadena california nasdaq arwr
PRESS RELEASE
May 28, 2010
Investor Relations Contacts:

Brandi Floberg
The Piacente Group, Inc.
212-481-2050
ir@arrowres.com

 


ARROWHEAD TO PRESENT AT NOBLE FINANCIAL SIXTH ANNUAL EQUITY CONFERENCE


PASADENA, Calif. –May 28, 2010– Arrowhead Research Corporation (NASDAQ: ARWR) today announced that Dr. Christopher Anzalone, Chief Executive Officer, will be presenting at the Noble Financial Sixth Annual Equity Conference at 10:30 a.m. EDT on June 8, 2010, at the Hard Rock Hotel in Hollywood, Florida.

The presentation will be webcast - audio / video / PowerPoint - live, and available for viewing at www.arrowheadresearch.com under the “Investor Relations” section of the Company’s website by selecting the “Presentations and Events,” tab. An archive of the presentation will be available for 90 days.

Arrowhead recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. You will need the SiverLight viewer (a free download from presentation link) to participate.

 




About Arrowhead Research Corporation

Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ: ARWR) is a nanotechnology company commercializing new technologies in the areas of life sciences and electronics. Arrowhead is seeking to build value for shareholders through the progress of its subsidiaries and investments. Currently, Arrowhead is focused primarily on its two majority owned subsidiaries; Unidym, a leader in carbon nanotube technology for electronic applications, and Calando, at the forefront of clinical application of RNAi delivery technology. Arrowhead also has minority investments in two privately held nanobiotech companies.